Pharmaceutical emulsion compositions comprising progestogen
Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.
1. A sterile, ready-to-use, pharmaceutical oil-in water emulsion composition for parenteral administration comprising in an aqueous medium:
0.015 to 1.2% wt/vol progestogen;
0.5-30% wt/vol oil wherein the oil comprises at least 85% wt/wt triglyceride based on the total oil content of the emulsion; and
0.0425-12.5% wt/vol phospholipid;
wherein the wt./wt. ratio of the progestogen to the oil is greater than or equal to about 1:32, and wherein the composition does not contain benzyl benzoate and does not contain medium chain triglycerides (MCT).
2. The pharmaceutical composition of claim 1 , containing about 0.03 to 0.63% wt./vol. progestogen.
3. The pharmaceutical composition of claim 1 , containing about 0.06 to 0.3% wt./vol. progestogen.
4. The pharmaceutical composition of claim 1 , further comprising a co-surfactant.
5. The pharmaceutical composition of claim 4 , wherein the co-surfactant is selected from the group consisting of oleate, oleic acid and combinations thereof.
6. The pharmaceutical composition of claim 4 , wherein the co-surfactant is present at a concentration of from about 0.005 to 1.0% wt./vol.
7. The pharmaceutical composition of claim 4 , wherein the co-surfactant to phospholipid ratio (wt./wt.) is within the range of about 1:85-1:12.
8. The pharmaceutical composition of claim 1 , further comprising an osmotic agent.
9. The pharmaceutical composition of claim 8 , wherein the osmotic agent comprises glycerol.
10. The pharmaceutical composition of claim 1 , wherein the progestogen is progesterone.
11. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is suitable for intravenous administration.
12. The pharmaceutical composition of claim 1 , having an osmolality between 200 to 1000 mOsm/kg.
13. The pharmaceutical composition of claim 1 , having an osmolality between 230-360 mOsm/kg.
14. The pharmaceutical composition of claim 1 , wherein the composition has a PFAT 5 value of ≦0.05%.
15. The pharmaceutical composition of claim 1 , wherein the emulsion comprises a dispersed oil phase with droplet particles having a volume-based mean diameter of ≦300 nm.
16. The pharmaceutical composition of claim 1 , wherein the emulsion comprises a dispersed oil phase with droplet particles having a volume-based mean diameter of ≦250 nm.
17. A method of administering a progestogen to a mammal comprising intravenously administering a pharmaceutical composition of claim 1 .
18. The method of claim 17 , wherein the mammal is suffering from or at risk of developing a condition that can be treated by the progestogen.
19. The method of claim 17 , wherein the mammal is suffering from or at risk of developing a traumatic central nervous system injury.
20. A method of manufacturing a pharmaceutical composition of claim 1 , comprising:
combining water, phospholipid and, optionally, an osmotic agent, to produce an aqueous composition;
combining progestogen and oil to produce an oily composition;
combining the aqueous composition and the oily composition and homogenizing to form a homogenous oil-in-water emulsion.